Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease

Official title

Feasibility and Tolerability Study of Wearing a Miniaturized Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease

Overview

Oculometry is becoming increasingly popular in fields such as enhanced reality and healthcare, but remains limited by complex devices that are poorly adapted to the needs of users, particularly the visually impaired. This research proposes to explore a smart contact lens (SCL)-based system to overcome these limitations, particularly for people with central visual deficits such as Stargardt's disease.

Detailed description

Eye tracking is becoming increasingly important in fields such as augmented reality such as augmented reality, virtual reality and healthcare (orthoptic rehabilitation), but is still limited by complex measurement methods that meet user needs.

In this context, the proposed research aims to study the feasibility of a system based on a smart contact lens that overcomes several overcome many of the limitations of current oculometers (sensitivity to environmental sensors, size, performance, etc.) and even more so when used by visually impaired people suffering from central vision deficits central vision deficit such as Stargardt's disease. Whether to eccentric fixation or to transmit relevant information about the environment relevant information about their environment, it is necessary to know direction of gaze. Unfortunately, current solutions are not always compatible with the difficulties faced by visually impaired and the SCL system could be a viable and effective solution.

Interventions

• Device SCL miniaturized scleral lens positioning
  1. Experimental evaluation: 1. TESTs withSCL system * Before positioning the SCL lens: slit lamp examination * After positioning the SCL lens: slit-lamp examination * Tests performed on projected screen. 2. Tests with a conventional oculometer: tests performed on a projected screen. 2. Ophthalmological assessment: 1. slit lamp examination 2. An end-of-study follow-up phone call.

Primary outcome measures

• Occurrence rate of adverse events, unexpected adverse events or serious adverse events [Time frame: 45 days]
• Ergonomics evaluation [Time frame: 45 days]

Eligibility criteria

Inclusion criteria

Patients with Stargardt disease

• Age: 18 - 70 ;
• Juvenile form of Stargardt's disease manifested by decreased visual acuity;
• Visual acuity greater than or equal to 20/400 in binocular vision;
• MMSE score without visual item ≥ 20/25 ;
• Eyes whose palpebral opening and ocular surface and its appendages allow the wearing of a scleral lens;
• Sufficient knowledge of the French language.
• Ability to give express, free and informed consent in person, after having received adequate information;
• Ability to comply with protocol requirements;
• Person covered by Health Insurance.

Healthy volunteers:

• Age: 18 - 70 years;
• Age- and sex-matched healthy volunteers to subjects with Stargardt's disease (± 5 years);
• MMSE score with visual items ≥ 25/30 ;
• Eyes with palpebral opening and ocular surface and appendages suitable for scleral lens wear;
• Visual acuity of at least 10/10 in binocular vision;
• Sufficient knowledge of the French language;
• Ability to give personal, express, written, free and informed consent after receiving adequate information ;
• Ability to comply with protocol requirements;
• Person covered by Health Insurance.

Exclusion criteria

For all participantsPersons referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant women, parturients, nursing mothers, persons deprived of liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or curatorship);

• Participants with neurodegenerative diseases or any other disease that could interfere with the planned evaluations during this study;
• Participants with ophthalmological diseases other than Stargardt's disease;
• Participants with a history of cleft palate, corneal infection, irregular cornea (such as keratoconus) and severe dry eye syndrome as determined by the ophthalmologist;
• Participants allergic or sensitive to methyl acrylic poly methacrylate (PMMA) or to any of the components of the Re-See lens;
• Participants allergic to tropicamide, atropine or its derivatives
• Participants at risk of angle-closure glaucoma;
• Participants allergic to sodium fluorescein;
• Suspicion of transmissible spongiform encephalopathy;
• Medications that may cause motor, visual or cognitive disorders (neuroleptics, etc.) or that may interfere with study evaluations;
• Participation in another clinical trial that could interfere with the present study;
• Inability to follow instructions or read. ☞Wearing glasses or contact lenses is not a non inclusion criterion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Supportive care

Study locations

France · 1 center

• Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts — Paris

Identifiers

NCT: NCT06989658 · P23-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗